Cambrex Corporation (NYSE:CBM) entered into a definitive agreement to acquire Avista Pharma Solutions from Ampersand Capital Partners and others for approximately $250 million on November 19, 2018. Under the transaction, Cambrex will pay to the stockholders of Avista an aggregate purchase price of $252 million, subject to certain adjustments, payable in cash at the closing of the transaction. This transaction will be funded with a combination of cash on hand and borrowings against the $500 million senior credit facility as expanded to utilize a portion of the accordion feature of that facility. Cambrex has secured committed financing for the proposed increase. Avista will operate as a wholly owned subsidiary of Cambrex. Avista's 330 person workforce will join Cambrex's 1,700 employees across the United States and Europe. The closing of the transaction is subject to customary closing conditions, including regulatory approvals, approval by shareholders of Avista, waiting period under the HSR Act shall have expired or been terminated, execution of Ancillary Agreements. The transaction is expected to close during the fourth quarter of 2018. Cambrex expects the transaction to be accretive to adjusted earnings per share in 2019. Wells Fargo Securities, LLC acted as the financial advisor and Paul M. Kinsella and Thomas J. Fraser of Ropes & Gray LLP acted as the legal advisor to Cambrex Corporation. Bourne Partners acted as the financial advisor and James Barrett and Ed Amer of Goodwin Procter LLP acted as the legal advisor to Avista Pharma Solutions. Cambrex Corporation (NYSE:CBM) completed the acquisition of Avista Pharma Solutions from Ampersand Capital Partners and others on January 2, 2019. Post merger, Avista will continue to survive as a wholly owned subsidiary of Cambrex. An aggregate purchase price of approximately $252 million in cash was paid to Avista’s stockholders as consideration and was funded with a combination of cash on hand and borrowings under a new senior secured credit facility, following a refinancing completed on the same day.